PMID- 28389620
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20181006
IS  - 1938-3673 (Electronic)
IS  - 0741-5400 (Linking)
VI  - 102
IP  - 2
DP  - 2017 Aug
TI  - Exploiting tumor-associated dendritic cell heterogeneity for novel cancer 
      therapies.
PG  - 317-324
LID - 10.1189/jlb.4MR1116-466R [doi]
AB  - Dendritic cells (DCs) are specialized APCs present in all tissues, including 
      tumors. They play a major role in orchestrating immune responses and were shown 
      to occur in various functional states in tumors. In this respect, immunogenic 
      tumor-associated DCs (TADCs) are required to initiate and sustain T 
      cell-dependent anti-cancer immunity, whereas regulatory TADCs harbor robust 
      immunosuppressive potential and accelerate malignant growth. Importantly, the 
      heterogeneity of the DC compartment in tumors has been dissected recently in 
      murine and human cancers and was shown to consist of developmentally distinct 
      subsets, including conventional DC (cDC)1, cDC2, and monocyte-derived DCs 
      (Mo-DCs). TADCs constitute an essential target in efforts to generate therapeutic 
      immunity against cancer, and the understanding of the complexity of the TADC 
      heterogeneity might prove important for therapeutic interventions targeted at 
      specific TADC subsets or their precursors. Hence, this review addresses the 
      differential functional specializations of ontogenically distinct TADC subsets.
CI  - (c) Society for Leukocyte Biology.
FAU - Keirsse, Jiri
AU  - Keirsse J
AD  - Myeloid Cell Immunology Lab, VIB-UGent Center for Inflammation Research, Ghent, 
      Belgium; and.
AD  - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 
      Brussels, Belgium.
FAU - Van Damme, Helena
AU  - Van Damme H
AD  - Myeloid Cell Immunology Lab, VIB-UGent Center for Inflammation Research, Ghent, 
      Belgium; and.
AD  - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 
      Brussels, Belgium.
FAU - Van Ginderachter, Jo A
AU  - Van Ginderachter JA
AD  - Myeloid Cell Immunology Lab, VIB-UGent Center for Inflammation Research, Ghent, 
      Belgium; and jvangind@vub.ac.be.
AD  - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 
      Brussels, Belgium.
FAU - Laoui, Damya
AU  - Laoui D
AD  - Myeloid Cell Immunology Lab, VIB-UGent Center for Inflammation Research, Ghent, 
      Belgium; and.
AD  - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 
      Brussels, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170407
PL  - England
TA  - J Leukoc Biol
JT  - Journal of leukocyte biology
JID - 8405628
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Neoplasms/*immunology
OTO - NOTNLM
OT  - DC vaccination
OT  - TADC
OT  - immunogenic DC
OT  - tolerogenic DC
EDAT- 2017/04/09 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/04/09 06:00
PHST- 2016/11/06 00:00 [received]
PHST- 2017/02/24 00:00 [revised]
PHST- 2017/03/13 00:00 [accepted]
PHST- 2017/04/09 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2017/04/09 06:00 [entrez]
AID - jlb.4MR1116-466R [pii]
AID - 10.1189/jlb.4MR1116-466R [doi]
PST - ppublish
SO  - J Leukoc Biol. 2017 Aug;102(2):317-324. doi: 10.1189/jlb.4MR1116-466R. Epub 2017 
      Apr 7.